NicOx Reports Results for the First Three Quarte... (ptions these forward-looking statements ...)

NicOx Reports Results for the First Three Quarters of 2008

Date:10/22/2008

ptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).

Consolidated Income Statement

Period of 9 months ended on

September 30, 2008 September 30, 2007

(in thousands of EUR except for per share data)

Revenues 2,943 18,398

Cost of goods and services (620) (1,647)

sold

Research and development expenses (51,348) (28,501)

Administrative and selling expenses (8,434) (8,811)

Other products 3,267 3,180

Operating loss (54,192) (17,381)

Net financial income 4,649 3,703

Loss before income (49,543) (13,678)

tax

Income tax expense (198) (27)

Loss for the period (49,741) (13,705)

Attributable to:

- Equity holders of the Company (49,741) (13,705)

- minority interests -
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing

Post Your Comments:

(Date:12/15/2009)... Reportlinker.com announces that a new market research ... The Future of Orphan Diseases ... Analysis and Reimbursement ,, ... Summary ,, The author has released ... Diseases Therapeutics - Market Forecasts to 2015, ...

(Date:12/15/2009)... Minn., Dec. 15 The Mosaic Company (NYSE: ... fiscal year 2010 earnings results and financial tables on ... on the New York Stock Exchange. Results will ... ,, The Company will host a conference call with ... the results. The call will begin at 11:00 ...

(Date:12/15/2009)... PHILADELPHIA and LONDON, Dec. 15 ... Thomson Pharma ® has become the first ... trial protocol and outcome information. This highly anticipated ... Pharma customers this month. ,, ... trial intelligence from registries, publications, press releases, conferences, ...

(Date:12/14/2009)... -- Vermillion, Inc. (Pink Sheets: VRML), a ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice ... will be joining its board of directors ... ,, "Bill brings more than 20 years ... biotechnology," said Gail Page, Vermillion Executive Chairperson. ...

[0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call [0] Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials [0] Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors

... BEDMINSTER, N.J., Feb. 29 NPS,Pharmaceuticals, Inc. (Nasdaq: ... executive vice president, chief operating officer, and chief,executive ... Brothers,Eleventh Annual Global Healthcare Conference in Miami on ... presentation will be available as a live,webcast with ...

... Kendle (Nasdaq: KNDL ), a,leading, ... Vice President and Chief Marketing Officer Simon,Higginbotham ... James,Institutional Investors Conference. The conference will be ... Orlando, March 2-5, 2008. Kendle,s,presentation is scheduled ...

... Tests Based on Company,s microRNA ... Technology on Schedule for 2008, REHOVOT, Israel and ... ROSG ), a leading,molecular diagnostics company, today reported a narrower operating ... corresponding,period of 2006, and said it remains solidly on target for ...

NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results

(Date:12/16/2009)... Tom Bowman, an expert in communicating scientific issues ... has developed a series of graphics that translate key ... (IPCC) report for public audiences. These new graphics provide ... to make informed decisions about climate change risks and ... means to clearly and accurately communicate findings in the ...

(Date:12/16/2009)... Dec. 2 DigitalPersona, Inc., a ... today announced an agreement with IBM to ... biometric fingerprint technology on IBM SurePOS 500 ... allows point-of-sale applications to more easily and ... can be linked to the individuals who ...

(Date:12/16/2009)... 2009 National Instruments (Nasdaq: ... and control, and DENSO Robotics, a leader ... technology, today announced their collaboration to integrate ... robotic arms. The collaboration increases productivity and ... manufacturing applications. In today,s trend toward high-mix, ...

Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2 DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2 National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2 National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3 National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4 National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5 Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 1 Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 2 Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 3 Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 1 Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 2 Go Red For Women 28R 29 Launches 12 Week Program to Improve Heart Health and Save Lives 47553 1 Go Red For Women 28R 29 Launches 12 Week Program to Improve Heart Health and Save Lives 47553 2 Go Red For Women 28R 29 Launches 12 Week Program to Improve Heart Health and Save Lives 47553 3

[0] Bowman creates graphic translation of climate change data [0] DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems [0] National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics

... cancer survivors might one day avoid the prospect of ... that would involve using stem cells derived from their ... studying the potential these cells may have for regenerating ... researchers hope to prove that an injection of fat-derived ...

... response to higher global temperatures may be somewhat overstated ... to adjust to changing conditions, according to researchers from ... published April 28 by Science, a team led by ... percent more carbon will be stored in plants and ...

... A jumping gene first identified in a cabbage-eating moth may ... gene therapy, researchers say. , , They compared the ... insert themselves into a cell's DNA and produce a desired ... radiation therapy. , They found the piggyBac transposon was five ...

Other Biology News:Fat stem cells being studied as option for breast reconstruction 2 Plants' role in global warming re-examined 2 Jumping gene could provide non-viral alternative for gene therapy 2 Jumping gene could provide non-viral alternative for gene therapy 3

Fat stem cells being studied as option for breast reconstruction Plants' role in global warming re-examined Jumping gene could provide non-viral alternative for gene therapy

One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....

MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...

SHEEP ANTI DEHYDROEPIANDROSTERONE...

This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...

Biology Products:

Albumin Colorimetric Assay Kit, QuantiChrom from BioAssay Systems Mouse Anti-Protein Kinase C Beta 2 Monoclonal Antibody, Unconjugated from AbD Serotec Sheep Anti-DEHYDROEPIANDROSTERONE (+DEAHS) Polyclonal Antibody, Unconjugated from AbD Serotec Protein Purification Applications from Promega

NicOx Reports Results for the First Three Quarte...(ptions these forward-looking statements ...)